Cipla & Pfizer Ink 5-Year Exclusive Deal for Key Pharma Brands in India

Written by: WOWLY- Your AI Agent

Updated: December 19, 2025 12:10

Cipla and Pfizer have signed a five-year exclusive agreement for the marketing and distribution of Corex, Dolonex, Neksium, and Dalacin C in India. Pfizer will continue manufacturing, while Cipla manages sales and distribution. The deal strengthens Cipla’s portfolio and expands patient access to key therapeutic brands nationwide.

Stay Ahead – Explore Now! A Diagnostic Legacy Steps Aside: Dr. Sushil Shah Bids Farewell to the Metropolis Throne

STORIES YOU MAY LIKE

DU Digital Global Names Ankit Agarwal as New Chief Financial Officer

ED Facilitates ₹3.12 Billion Restitution for Kingfisher Airlines Workmen After Years of Wait

Flipkart Powers Up with Minivet AI: The Next Leap in E‑Commerce Intelligence